Evidence map›Paper›PMID 24388573›Full record

ArticleThrombosis research2014

Venous thromboembolism in children with cancer - a population-based cohort study.

Alex J Walker, Matthew J Grainge, Tim R Card, Joe West, Susanna Ranta, Jonas F Ludvigsson

Abstract read
In one paragraph

Article in Thrombosis research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Thrombotic Complications in Pediatric Cancer.Children (Basel, Switzerland) · 2024
    Review
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Long-Term Risk of Venous Thromboembolism in Survivors of Childhood Cancer: A Report From the Childhood Cancer Survivor Study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2018
    Article
  15. Review
  16. Review
  17. Article
  18. USE OF WARFARIN IN PEDIATRICS: CLINICAL AND PHARMACOLOGICAL CHARACTERISTICS.Revista paulista de pediatria : orgao oficial da Sociedade de Pediatria de Sao Paulo
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Alex J WalkerDivision of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital, NG5 1PB UK; Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit. Electronic address: alex.walker@nottingham.ac.uk.
Matthew J GraingeDivision of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital, NG5 1PB UK; Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit.
Tim R CardDivision of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital, NG5 1PB UK; Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit.
Joe WestDivision of Epidemiology and Public Health, University of Nottingham, Nottingham City Hospital, NG5 1PB UK; Nottingham Digestive Diseases Centre, NIHR Biomedical Research Unit.
Susanna RantaChildhood Cancer Research Unit, Karolinska Institutet Stockholm Sweden.
Jonas F LudvigssonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet Sockholm Sweden; Department of Pediatrics, Örebro University Hospital, Örebro University, Örebro Sweden.

Funding

Cancer Research UK 12079Cancer Research UK C17683/A12079
6 · The paper itself

Abstract

introductionCancer is a known risk factor for venous thromboembolism (VTE) in adults, but population-based data in children are scarce. MATERIALS AND

methodsWe conducted a cohort study utilising linkage of the Clinical Practice Research Database (primary care), Hospital Episodes Statistics (secondary care), UK Cancer Registry data and Office for National Statistics cause of death data. From these databases, we selected 498 children with cancer diagnosed between 1997 and 2006 and 20,810 controls without cancer. We calculated VTE incidence rates in children with cancer vs. controls, and hazard ratios (HRs) using Cox regression.

resultsWe identified four VTE events in children with cancer compared with four events in the larger control population corresponding to absolute risks of 1.52 and 0.06 per 1000 person-years respectively. The four children with VTE and cancer were diagnosed with hematological, bone or non-specified cancer. Childhood cancer was hence associated with a highly increased risk of VTE (HR adjusted for age and sex: 28.3; 95%CI=7.0-114.5).

conclusionsChildren with cancer are at increased relative risk of VTE compared to those without cancer. Physicians could consider thromboprophylaxis in children with cancer to reduce their excess risk of VTE however the absolute risk is extremely small and the benefit gained therefore would need to be balanced against the risk invoked of implementing such a strategy. NOVELTY & IMPACT STATEMENTS: While there is a reasonable level of knowledge about the risk of VTE in adult populations, it is not well known whether this risk is reflected in paediatric patients. We found a substantial increase in risk of VTE in children with cancer compared to a child population without cancer. While this finding is important, the absolute risk of VTE is still low and must be balanced with the risks of anticoagulation.

Indexed as

AdolescentChildChild, PreschoolCohort StudiesFemaleHumansMaleNeoplasmsRisk FactorsThromboembolismUnited KingdomVenous ThromboembolismCancerChildrenMalignancyThromboembolismVenous thrombosis

Identifiers

PMID24388573
PMCPMC3969718

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.